フックス角膜内皮ジストロフィー（FECD）市場 - 競合情勢

2024年には、主要16カ国において、フックス角膜内皮ジストロフィー（FECD）の総有病者数は1億3,300万人を超えると予想されています。現在、FECDに対してFDAが承認した治療薬はありません。FECDに関する最新のガイドラインは米国眼科学会によって作成されました。

FECDのパイプラインは、主に酵素阻害剤Rhoキナーゼ2阻害剤とmTOR（哺乳類ラパマイシン標的）阻害剤で構成されています。

FECDを対象とした世界の臨床試験の約59％は北米地域で実施され、次いで欧州が26.47％、アジア太平洋が14.7％となっています。

過去10年間に実施されたFECDの開発企業が関与する取引では、欧州とアジア太平洋地域でパートナーシップ別取引が主流でした。

当レポートでは、世界のフックス角膜内皮ジストロフィー（FECD）市場について調査し、疾患の概要とともに、治験動向、パイプライン概要、将来の見通しなどを提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 疾患の情勢

• 疾患の概要
• 疫学の概要
• 治療の概要

第4章 上市済み薬剤の評価

• 主な市販薬
• 作用機序別概要
• 投与経路別概要
• 市販薬のプロファイルと売上予測

第5章 価格設定と償還評価

• 年間治療費
• 価格設定と償還までの時間

第6章 パイプライン薬剤の評価

• 第Ⅲ相パイプライン薬剤
• 開発段階別概要
• 分子タイプ別概要
• 作用機序別概要
• 投与経路別概要
• 医薬品特異的相転移成功率（PTSR）と承認の可能性（LoA）
• 治療領域および適応症固有のPTSRおよびLoA

第7章 臨床試験の評価

• 過去の概要
• フェーズ別概要
• ステータス別概要
• 進行中および計画中の試験のフェーズ別概要
• 仮想コンポーネントを使用した治験
• 地理的概要
• 地域別の単一国および多国籍試験
• 上位20社のスポンサーとフェーズ別内訳
• 上位20社のスポンサーのステータス別内訳
• エンドポイントステータス別概要
• 人種および民族別の概要
• 登録データ
• 治験サイトの上位20か国
• 世界の上位20サイト
• 実現可能性分析- 地理的概要
• 実現可能性分析- ベンチマークモデル

第8章 取引の情勢

第9章 商業的評価

• 主要な市場参入企業

第10章 将来の市場促進要因

第11章 付録

This reports provides a data-driven overview of the current and future competitive landscape in FECD therapeutics.

• More than 133,000,000 total prevalent cases of FECD are expected in 2024 in the 16 countries covered in GlobalData's epidemiology forecast for FECD.
• Currently there are no FDA approved therapies for FECD. The most recent guideline for FECD was developed by the American Academy of Ophthalmology.
• The pipeline for FECD mainly consists of enzyme inhibitors Rho kinase 2 inhibitor and mTOR (mammalian target of rapamycin) inhibitor.
• Around 59% of worldwide trials addressing FECD were conducted in the North America region, followed by Europe with 26.47% of trials and Asia-Pacific with 14.7% of the total trials.
• In deals involving companies developing FECD assets that occurred during past 10 years, partnership emerged as the dominant deal type in Europe and Asia-Pacific.

Scope

GlobalData's FECD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the FECD market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global FECD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

• 5.1 Annual Therapy Cost
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer